These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

882 related articles for article (PubMed ID: 28373190)

  • 1. Delamanid Kills Dormant Mycobacteria
    Chen X; Hashizume H; Tomishige T; Nakamura I; Matsuba M; Fujiwara M; Kitamoto R; Hanaki E; Ohba Y; Matsumoto M
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
    Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.
    Kwon YS; Jeong BH; Koh WJ
    Expert Opin Pharmacother; 2015 Feb; 16(2):253-61. PubMed ID: 25327169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs.
    Dutta NK; Illei PB; Peloquin CA; Pinn ML; Mdluli KE; Nuermberger EL; Grosset JH; Karakousis PC
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3726-31. PubMed ID: 22547623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
    de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE
    Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910.
    Lenaerts AJ; Hoff D; Aly S; Ehlers S; Andries K; Cantarero L; Orme IM; Basaraba RJ
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3338-45. PubMed ID: 17517834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen.
    Dutta NK; Alsultan A; Gniadek TJ; Belchis DA; Pinn ML; Mdluli KE; Nuermberger EL; Peloquin CA; Karakousis PC
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3910-6. PubMed ID: 23733473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profile of delamanid for the treatment of multidrug-resistant tuberculosis.
    Szumowski JD; Lynch JB
    Drug Des Devel Ther; 2015; 9():677-82. PubMed ID: 25678771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures.
    Walter K; Te Brake LHM; Lemm AK; Hoelscher M; Svensson EM; Hölscher C; Heinrich N
    J Antimicrob Chemother; 2024 Oct; 79(10):2607-2610. PubMed ID: 39110473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH.
    Iacobino A; Giannoni F; Pardini M; Piccaro G; Fattorini L
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31010861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis.
    Blair HA; Scott LJ
    Drugs; 2015 Jan; 75(1):91-100. PubMed ID: 25404020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Trends in tuberculosis treatment duration].
    Veziris N; Aubry A; Truffot-Pernot C
    Presse Med; 2006 Nov; 35(11 Pt 2):1758-1764. PubMed ID: 17086138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects.
    Mallikaarjun S; Wells C; Petersen C; Paccaly A; Shoaf SE; Patil S; Geiter L
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5976-85. PubMed ID: 27458223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig.
    Ahmad Z; Klinkenberg LG; Pinn ML; Fraig MM; Peloquin CA; Bishai WR; Nuermberger EL; Grosset JH; Karakousis PC
    J Infect Dis; 2009 Oct; 200(7):1136-43. PubMed ID: 19686043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.
    Matsumoto M; Hashizume H; Tomishige T; Kawasaki M; Tsubouchi H; Sasaki H; Shimokawa Y; Komatsu M
    PLoS Med; 2006 Nov; 3(11):e466. PubMed ID: 17132069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delamanid: first global approval.
    Ryan NJ; Lo JH
    Drugs; 2014 Jun; 74(9):1041-5. PubMed ID: 24923253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fighting tuberculosis by drugs targeting nonreplicating
    Iacobino A; Piccaro G; Giannoni F; Mustazzolu A; Fattorini L
    Int J Mycobacteriol; 2017; 6(3):213-221. PubMed ID: 28776518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Bedaquiline, Pyrazinamide, Levofloxacin, Linezolid, and Clofazimine Second-line Regimen for Tuberculosis Displays Similar Early Bactericidal Activity as the Standard Rifampin-Based First-line Regimen.
    Zainabadi K; Vilbrun SC; Mathurin LD; Walsh KF; Pape JW; Fitzgerald DW; Lee MH
    J Infect Dis; 2024 Aug; 230(2):e447-e456. PubMed ID: 38060827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.